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Abstract
Postoperative radiation therapy substantially decreases local relapse and moderately reduces
breast cancer mortality, but can be associated with increased late mortality due to cardiovascular
morbidity and secondary malignancies. Sophistication of breast irradiation techniques, including
conformal radiotherapy and intensity modulated radiation therapy, has been shown to markedly
reduce cardiac and lung irradiation. The delivery of more conformal treatment can also be achieved
with particle beam therapy using protons. Protons have superior dose distributional qualities
compared to photons, as dose deposition occurs in a modulated narrow zone, called the Bragg
peak. As a result, further dose optimization in breast cancer treatment can be reasonably expected
with protons. In this review, we outline the potential indications and benefits of breast cancer
radiotherapy with protons. Comparative planning studies and preliminary clinical data are detailed
and future developments are considered.
Background
Postoperative radiation therapy very substantially
improves local control in the treatment of both early and
locally-advanced breast cancer. Trial overviews indicate
that for every four local failures prevented, one fewer
death from breast cancer can be expected. However, this
long-term benefit can be mitigated somewhat by excess
mortality due to cardiovascular disease and secondary
malignancies [1]. Although local radiotherapy limited to
the breast or chest wall can usually be administered using
simple planning techniques with minimal late toxicity,
regional treatment including lymph nodal areas can
expose non-target organs to substantial radiation doses.
One of the principal goals of treatment planning is thus to
reduce any potential negative consequences of radiother-
apy on long-term morbidity and mortality. This repre-
sents a particularly difficult challenge in the setting of
loco-regional radiotherapy.
In recent years, great advances have been made in the
planning and delivery of radiotherapy, as well as the
development of existing imaging modalities. Computer-
ized planning systems in conjunction with modern imag-
ing studies are routinely used in breast cancer treatments.
Three-dimensional conformal radiotherapy and, more
recently, intensity modulated radiation therapy (IMRT)
are being implemented increasingly in clinical use [2-6].
The delivery of optimal dose conformation can also be
achieved with protons. Proton beam therapy is character-
ized by remarkable depth-dose distributions that have a
low to median entrance dose, followed by a unified high-
dose region (Bragg peak region) in the tumor area, fol-
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lowed by a steep fall-off to zero-dose distal to the target.
As a result, physical dose distributions with protons are
both highly conformal and homogeneous. Several proton
facilities are currently operating worldwide and many
more are scheduled to open in coming years. Proton beam
therapy, however, is more costly than conventional treat-
ment, and any potential benefits must be assessed in the
light of the associated costs to the health-care system.
Although comparative treatment-planning studies have
demonstrated the superior dose conformation achievable
with proton beams, it remains unclear whether protons
can achieve substantial clinical gains in cancer types other
than ocular melanoma or skull-base tumors. The indus-
try-driven enthusiasm generated by proton dose distribu-
tions should not be allowed to outpace the clinical data
investigating efficacy and safety in specific tumor sites.
This review details the different proton beam delivery sys-
tems, with special emphasis upon the technical challenges
of producing and delivering proton treatment beams for
breast tumors. Dose-comparison studies of proton and
photon beam therapy for breast cancers are reviewed, pre-
liminary clinical data are detailed and future development
considered.
Proton beam therapy: delivery systems and biologic effects
The beam delivery system is the technical component that
lies between the cyclotron and the patient. This system
monitors patient dose, generates the desired 3D dose dis-
tribution within the patient and may also provide
dynamic monitoring of its beam spreading and range con-
trol functions (see dynamic scanning technique). Two
beam line designs are commonly used for proton therapy
[7]. The scatter foil technique utilizes beam-flattening
devices, collimators, scatterers, and energy modulation
devices in the beam line to obtain a homogeneous dose in
the target and sharp lateral penumbra [8]. Additionally,
for each proton field, an individual aperture and compen-
sator is manufactured and positioned in the proton beam
[9]. Compensators will conform the distal dose fall-off to
the target volume. In essence, it is a passive delivery sys-
tem that relies on multiple coulombic scattering within
the scattering foil devices for lateral beam spreading. A
disadvantage of passive spreading is the interdependence
of beam range and field size [8]. As field size increases, the
scattering foil thickness must increase accordingly, result-
ing in loss of maximum treatment range. Most of the pro-
ton treatment facilities employ this simple and reliable
delivery system.
As opposed to photons, protons are charged particles and
can be easily deflected by the action of magnetic fields
under computer control [7]. This opens the possibility for
dynamic scanning, which can provide beam spread-out
modulation by magnetically scanning the protons, with
external apertures and compensators to conform the dose
distribution. In dynamic scanning, no inherent interde-
pendence of beam range and field size is observed. The
ultimate dynamic scanning system is voxel scanning ('spot'
or 'raster' scanning) [10-12], in which the beam is decom-
posed into multiple, three dimensionally distributed
Bragg peaks, which completely cover the target volume.
Each voxel is irradiated to the planned dose, and the beam
is switched off while moving to the adjacent voxel (spot
scanning) [13]. This system is currently used at the Paul
Scherrer Institut (PSI). Another active delivery system is
the raster scan system that is used for carbon-ion radiother-
apy at the Gesellschaft für Schwerionenforschung mbH,
Darmstadt, Germany [14]. This active scanning system is
based on the continuous irradiation with a radiation pen-
cil beam through the target volume. A Belgian manufac-
turer (Ion Beam Applications) is currently implementing
this delivery system for clinical use in the Boston proton
beam facility. At PSI 3D dose conformation is generated
without the need of external devices. Potential disadvan-
tages include loss of precise tissue inhomogeneity com-
pensation and potential increase in the lateral dose fall-off
for beams that are conformed without external apertures.
Furthermore, quality assurance is a more complex process
for dynamic systems. External apertures, compensators
and modulator wheels can be readily coded and identified
in passive systems, but higher technology is involved to
monitor beam spot motion and field uniformity. Note-
worthy, the secondary neutron dose given to the patient
with this beam delivery method might be lower by a factor
of 10, when compared to the scatter foil technique. Vari-
ous dose comparative studies have shown undisputedly
that protons, when compared to photons, administer a
lower integral dose to the patient [15,16]. This integral
dose may cause secondary cancers. The production of sec-
ondary neutrons by the proton beam could however
increase this integral dose and thus abrogate substantially
the advantage of proton beam therapy for breast cancer.
As such, the neutron dose has to be kept as minimal as
possible. With spot scanning, the neutron dose in the
Bragg Peak region can reach 1% of the treatment dose, but
in the non-target volume this dose is roughly 2 – 4 × 10-3
equivalent-dose (sievert) per Gy with the spot scanning
technique and can be considered negligible [17]. Second-
ary neutrons are produced as a result of patient and mate-
rial located in the proton beam path interaction,
respectively. Hence, the production of these particles is
dependent on the design of the beam line. Improving it
(particularly the design and geometry of the Gantry's noz-
zle) might however decrease substantially the neutron
dose with the scatter foil technique (A Thornton, PTCOG
44, personal communication). The neutron issue has
been recently assessed in a review on IMRT and proton
beam therapy [18].Radiation Oncology 2006, 1:22 http://www.ro-journal.com/content/1/1/22
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It must be emphasized that protons have biologic effects
in tissue similar to those of the megavoltage photons used
in conventional therapy. They are regarded as low linear
energy transfer particles, unlike other non-conventional
radiotherapy particles, such as neutrons or carbon ions.
The Relative Biological effectiveness of protons is defined
as the ratio of the dose of a reference beam (usually 60Co
or 6 MV) required to produce a specific effect in a biolog-
ical system to the physical dose of proton radiation
required to produce the same effect [19]. Its value is not
fixed, but for 70 – 250 MeV protons range typically form
0.9 to 1.9, with an accepted 'generic' value of 1.1 in clini-
cal proton therapy [20]. Consequently, the equivalent
60Co photon dose is the proton dose multiplied by 1.1.
This calculated dose is defined as the Cobalt Gray Equiva-
lent (CGE) dose. On behalf of the International Commis-
sion on Radiation Units and Measurements and the
International Atomic Energy Agency, a committee will
submit a report on Prescribing, Recording and Reporting
Proton beam therapy in early spring 2006. It is proposed
that the unit of Gy-isoeffective will be designated Gy(I).
The full report will be published early 2007 (Dan Jones,
personal communication 2006).
Rationale for proton beams for breast cancer therapy
Photon whole breast irradiation (WBI) with two tangen-
tial fields sometimes administers substantial dose to the
lung and, for left-sided breast cancers, to portions of the
heart. When regional irradiation is indicated, the dose
administered to these and other organs-at-risk (OARs) can
be substantially increased. For this reason, a mixture of
photon and electron beams is often used to treat the inter-
nal mammary nodes. Because of the need to match the
electron and photon fields, this technique is characterized
by considerable target dose inhomogeneity. Moreover,
photon-beam irradiation of axillary lymph nodes also
produces substantial dose inhomogeneities regardless of
the technique used [21]. Newer radiotherapy techniques
have permitted dose delivery to be conformed more pre-
cisely to the target volume. Tangential IMRT improves the
dose homogeneity of WBI and reduces the dose to the
heart or lung [2,3]. Similarly, IMRT techniques can
improve homogeneity of dose delivery to the chest wall
and internal mammary nodes for post-mastectomy radio-
therapy, albeit at a cost of an increased dose to portions of
the contra-lateral lung and breast [4]. Additionally, IMRT
may decrease the administered dose to the abdominal
organs when compared with conventional radiotherapy
using physical wedges [6]. Using automated beam orien-
tation and modality selection (electrons vs. IMRT), modu-
lated electron radiotherapy has also resulted in an
increased dose sparing to OARs with a somewhat less
homogeneous target-dose delivery when compared to
photon beams only [22]. Proton planning can also result
in unparalleled homogeneous dose distributions within
complex target volumes, while simultaneously sparing
neighboring OARs. Comparative treatment planning
studies have shown consistently that proton beam therapy
can substantially decrease dose to OARs for various
tumors [23-29]. This radiation modality could thus be
delivered for the treatment of early or locally-advanced
breast cancers. This review discussed several potential
indications for the use of proton beams in breast cancer
therapy.
Methods
This review is based on Medline and PubMed literature
searches using the key words 'breast neoplasm', 'radio-
therapy', 'proton beam therapy', and the authors' clinical
experience.
Whole breast and loco-regional irradiation with protons
Meta-analyses of available randomized data by the Early
Breast Cancer Trialists Collaborative Group have shown
that radiation therapy decreases local recurrence rates by
about 70% compared with surgery alone [1]. Absolute
reductions of around 5% in 15-year breast-cancer mortal-
ity have been demonstrated both for patients treated with
breast irradiation following conservation surgery and for
node-positive patients treated with loco-regional irradia-
tion following mastectomy. Although irradiation limited
to the breast has not been shown to be associated with
excess intercurrent mortality, about 1% more deaths due
to causes other than breast cancer were observed among
patients having receiving loco-regional post-mastectomy
radiotherapy. This excess mortality was principally due to
cardiac and other vascular causes, and to a lesser extent to
secondary malignancies, particularly pulmonary [1]. An
increased incidence of contralateral breast cancers was
also observed in irradiated patients. Photon radiotherapy
has also been associated with a small but incremental
increase of long-term risk of contralateral breast cancer in
a large SEER series [30] and data stemmed from rand-
omized trials (Early Breast Cancer Trialists' Collaborative
Group overview) [1]. Interestingly, the use of techniques
that minimize cardiac dose, such as the use of electron
beams to treat the mammary nodes and the chest wall,
have been specifically used in two more recent post-mas-
tectomy trials [31,32]; these particular studies do not
show any deleterious effect of radiotherapy on cardiovas-
cular mortality. These considerations demonstrate that
maximizing dose sparing to the heart, or other OARs, such
as the lung and contralateral breast, is of paramount
importance both in early and locally-advanced breast can-
cer.
In the irradiation of breast and regional lymph nodes, we
have previously shown that protons, when compared to
conventional or IMRT, deliver a highly homogeneous
treatment with a substantial decrease of the mean doseRadiation Oncology 2006, 1:22 http://www.ro-journal.com/content/1/1/22
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delivered to the heart and contralateral lung alike [33]. In
the PSI study, a two-field spot-scanned proton (left and
anterior oblique fields), 9-fields (coplanar) IMRT (15 MV)
and conventional plans (wedged 6 MV opposed tangen-
tial fields with anterior field to treat the internal mam-
mary nodes using 26 Gy with 6 MV photons and 24 Gy
with 12 MeV electrons) were computed and compared for
a breast cancer patient. Mean doses delivered to the ipsi-
lateral lung and heart were lower with protons. Moreover,
the dose delivered to the contralateral breast was substan-
tially reduced with protons, when compared to IMRT. For
this OAR, the average values of the mean and maximum
doses were 0.02 – 1.4 and 8.0 – 21.6 CGE-Gy for the pro-
ton and IMRT planning, respectively. This can be observed
in the dose-volume histogram of the planned target vol-
ume (Fig. 1) and the OARs in the vicinity of the target vol-
ume (Fig. 2a, 2b). Likewise, Johansson et al. [34] reported
on 11 node positive left-sided breast cancer patients for
which one proton, one IMRT and two conventional plans
were computed, respectively, for each patient. Irradiation
techniques consisted on one single lateral oblique beam
(30°), 6-fields (coplanar) 6 MV photon beams and tan-
gential beams, with or without electron fields, for the pro-
ton (passive delivery technique), IMRT and conventional
plans, respectively. The target volumes included the
remaining breast parenchyma, the internal mammary
nodes, and the supraclavicular-axillary lymph node
regions. The prescribed dose was 50 CGE-Gy. According
to a normal tissue complication probability (NTCP)
model, protons reduced the NTCP for heart by a factor of
4 and for the lung by a factor of >20, when compared to
the best photon plans. Although radiation pneumonitis
generally represents a relatively minor clinical problem,
potentially reducing the cardiac mortality from 6.7%,
with the tangential technique, to only 0.5% with protons
is likely to be clinically relevant, as a substantial number
of patients, even those with positive nodes, will remain
alive to be at risk for long-term morbidity [34]. Moreover,
modern systemic adjuvant treatments, such as anthracy-
cline-based chemotherapy, with or without taxanes, or
trastuzumab [35], are associated with cardiotoxicity.
High-dose delivery to the heart may further increase this
risk in combination with these chemotherapy agents.
Maximum heart distance and mean lung dose has been
associated with cardiotoxicity in photon radiotherapy
series [36]. IMRT significantly reduces the mean dose of
the contralateral breast when compared to non-IMRT con-
ventional tangential techniques [37], albeit at a cost of
increased normal tissue radiation exposure [18]. Proton
Cumulative dose-volume histograms for the conventional  photon (Conventional), the intensity modulated treatment  (IMRT 1–2) and theproton (Protons) plans for the heart [33] Figure 2a
Cumulative dose-volume histograms for the conventional 
photon (Conventional), the intensity modulated treatment 
(IMRT 1–2) and theproton (Protons) plans for the heart [33]. 
(B) Cumulative dose-volume histograms for the conven-
tional photon (Conventional), the intensity modulated treat-
ment (IMRT 1–2) and the proton (Protons) plans for the 
ipsilateral lung [33].
A
PROTONS
IMRT - PLAN B 
IMRT - PLAN A
CONVENTIONAL
B
PROTONS
IMRT - PLAN B 
IMRT - PLAN A
CONVENTIONAL
Cumulative dose-volume histograms for the conventional  photon (Conventional), the intensity modulated treatment  (IMRT 1–2) and the proton (Protons) plans for the breast  and the breast and regional lymph nodes [33] Figure 1
Cumulative dose-volume histograms for the conventional 
photon (Conventional), the intensity modulated treatment 
(IMRT 1–2) and the proton (Protons) plans for the breast 
and the breast and regional lymph nodes [33].
CONVENTIONAL
IMRT - PLAN B 
PROTONS
IMRT - PLAN ARadiation Oncology 2006, 1:22 http://www.ro-journal.com/content/1/1/22
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beam therapy further decreases the parasitic dose to the
contralateral breast and nullifies the integral dose deliv-
ered to the patient [33]. Consequently, the implementa-
tion of radiation techniques that lower the integral dose of
OARs in vicinity of the breast, such as protons, could be
recommended for certain clinical situation (e.g., node
positive left-sided tumors or inner tumor quadrant locali-
zation for young patients with large breasts).
Using biological parameters among other factors and a
simple spot-scanned proton beam therapy technique (sin-
gle-field), Fogliata et al. have demonstrated that protons
reduce the lung equivalent uniform dose (EUD) signifi-
cantly in both right- and left-sided tumors, when com-
pared to other non-proton techniques (including IMRT)
for postoperative whole breast radiotherapy [38]. Unlike
the PSI [33] and Uppsala [34] study, the internal mam-
mary chain, supraclavicular and axilla region was not part
of the treatment volume for this planning-comparison
exercise involving 5 patients with early breast cancer.
Interestingly, the mean heart dose for the subset of
patients with left-sided tumors was identical (mean, 2.6
CGE-Gy; range 2.2 CGE – 2.9 Gy). Maximum heart dose,
however, was reduced with protons: a 40% absolute dose-
decrease in hot spots was calculated with a single 100 MeV
proton beam when compared to non-proton techniques.
This derives from the heavily weighted heart-dose con-
straints applied to the optimization process of the IMRT
planning with its consequential increased dose adminis-
tered in the lung when compared to proton planning
(lung volume receiving 20 CGE-Gy: 6% vs . 20% for pro-
tons and IMRT, respectively).
Table 1 details the planning target volume and doses
administered to OARs for 17 breast cancer patients
planned with protons and photons, with or without
IMRT. On the average, 97% of the PTV receives 95% of the
prescribed dose with protons compared to only 89% with
conventional photon techniques. With protons, the mean
dose to the heart is reduced by a factor of two to three
when compared to photon planning, with or without
IMRT. In these published studies proton plans have been
calculated using only one [34,38] or two [33] fields. Such
simple techniques could be easily used in a busy radiation
oncology department. In contrast, for IMRT plans, sophis-
ticated techniques were required in order to meet the
planning goals and OAR's dose-constraints, resulting in
an increased number (mean, 5) of beams. Overall, com-
parative planning studies have shown consistently that
protons can reduce the administered dose to the heart,
lung and contralateral breast in the treatment of breast
with or without regional irradiation. It is possible that fur-
ther proton dose optimization could be achieved by
added proton field directions, resulting in an additional
degree of dosimetric freedom.
Partial breast irradiation with protons
Whole-breast irradiation with tangential photon beams is
considered standard treatment following breast-conserv-
ing surgery. However, the inconvenience associated with
conventional fractionation, and the substantial workload
that breast cancer represents in busy radiation oncology
departments, have led to increasing interest in other
options for these patients. This subject has been reviewed
elsewhere [39]. As most local failures after conservation
surgery occur in the vicinity of the primary tumor bed,
limiting the target volume to this area might achieve an
acceptable degree of local control for selected patients
whose tumors seem unlikely to be multifocal. The smaller
irradiated volume may also more readily allow radiother-
apy to be markedly accelerated, or even to be applied in a
single fraction. This would substantially reduce the incon-
venience associated with WBI, particularly for patients liv-
ing far from treatment centers. Some of the acute and
chronic toxicity of WBI might also be avoided, thereby
improving patient satisfaction with treatment. Several ret-
rospective accelerated partial breast irradiation (APBI)
series [40-43] have appeared in the literature, and pro-
spective randomized trials comparing WBI vs. APBI are
ongoing (RTOG, GEC-ESTRO, Targit trial). APBI can be
delivered using several techniques, namely low- and high-
dose rate (HDR) brachytherapy using interstitial implan-
tation [41,43-45] or a balloon catheter (MammoSite Radi-
ation Therapy System; Cytyc Corp. Alpharetta, GA, USA)
[46], 3D external beam conformal radiation therapy [47]
or intraoperative radiotherapy (electrons or soft X-rays)
[48,49]. Biologic comparison of APBI protocols has been
recently reviewed [50]. Similarly with WBI, APBI could
also be delivered using protons. Fig. 3 shows the dose dis-
tribution in an axial CT slice through the center of the
breast using spot-scanning proton beam technology and a
1 field (direct) beam arrangement. This proton therapy
planning was done on a patient treated at the Massachu-
setts General Hospital. The defined target volume con-
sisted of the lumpectomy cavity plus a 20 mm margin.
Taghian et al. have published the dosimetric comparison
of APBI using protons with 3D conformal photon/elec-
tron based radiotherapy in 17 patients with early breast
cancer [51]. PTV coverage for both modalities was equiv-
alent. The maximum and median dose delivered to the
heart, ipsilateral lung and non target breast tissue was
however significantly decreased with protons for all
patients. The Boston cohort has been recently updated
and the initial clinical experience of 25 patients treated
with APBI using proton beam therapy reported [52].
Using BID fractionation, 32 CGE was delivered to in 4
days, using 1 to 3 protons fields. To be enrolled in this
phase I/II clinical trial, breast cancer patients had to have
unifocal ≤2 cm tumors, negative margins (>2 mm) and
pathologically negative axillary lymph nodes. The median
volume of nontarget breast tissue receiving 50% of theRadiation Oncology 2006, 1:22 http://www.ro-journal.com/content/1/1/22
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prescribed dose was 23% and the median dose received by
5% of the ipsilateral lung was only 1.3 CGE. The contro-
lateral lung and heart received essentially no irradiation.
After observing acute moist desquamation at the treat-
ment site in 3 patients treated with a single proton field,
the treatment technique was refined and skin sparing was
improved by the use of multiple (2–3) fields. These clini-
cal data from Boston suggest that APBI using protons is
technically feasible and provide optimal OAR sparing.
Similarly, proton beam therapy could be delivered for
simultaneous integrated boost delivery (SIB) during WBI.
Notwithstanding the importance of the boost delivery on
local control [53,54], this additional radiation dose could
be delivered not sequentially but concomitantly to the
WBI. This would allow reduction of the overall treatment
time by 1.5 – 2 weeks by delivering the boost to the tumor
bed simultaneously with the whole breast schedule. Giv-
ing higher fractional boost doses (≈2.2 – 2.4 CGE-Gy/frac-
tion) will administer higher biological equivalent dose
(BED) to the target volume. As the dose distributions
achieved with IMRT or protons are highly conformal,
OARs (heart, lung) that are not directly surrounding the
target regions will not receive a higher dose per fraction
and are therefore not at greater risk for late toxicity. Fur-
thermore, this type of concomitant boost schedule is a
more efficient way of planning and radiation delivery as it
involves the use of the same plan for the entire course of
treatment. This SIB strategy is however a significant depar-
ture from conventional radiotherapy experience. Radia-
tion therapy schedules are aimed at giving a high uniform
dose to the target volume for every fraction and then
reducing the volume to the boost portion. SIB has been
mostly studied for head and neck and prostate cancers
and occasionally for breast cancer in recent years [55]. A
Stanford study, however, has demonstrated that a SIB-
Dose distribution (protons) in an axial CT slice through the  center of the breast for an early breast cancer patient  treated with partial breast irradiation Figure 3
Dose distribution (protons) in an axial CT slice through the 
center of the breast for an early breast cancer patient 
treated with partial breast irradiation. The isodose contours 
are represented by different colors (corresponding values 
are displayed on the upper-right border of the figure).
Table 1: Overview of dose-volume histograms with proton, IMRT and photon conventional planning for the PTV and OARs in the 
proton-photon planning comparison literature
PTV/OARs 
Series (ref. no.)
V95% Protons 
(mean)
V95% IMRT (mean) V95% Photons 
(mean)
Mean Dose (%) 
Protons
Mean Dose (%) 
IMRT
Mean Dose (%) 
Photons
PTV (breast only)
Lomax et al. [33] 97.1 92.2 86.6
Johansson et al. 
[34]
94.0 85.9 88.8
Fogliata et al. [38] 99.8 95.5 92.2
Heart
Lomax et al. [33] 11.6 24.0 29.3
Johansson et al. 
[34]
21.0* 41.0* 61.0*
Fogliata et al. [38] 4.4 5.6 5.0
Lung (ipsilateral)
Lomax et al. [33] 25.0 33.0 33.3
Johansson et al. 
[34]
1.0* 18.0* 29.0*
Fogliata et al. [38] 7.0 17.1 22.5
IMRT, intensity modulated radiotherapy; PTV, planning target volume; OAR, organ at risk; V95%, volume (in percentage) receiving 95% of the 
prescribed dose.
*estimated % of the prescribed dose from the dose-volume histograms administered to the heart and lungRadiation Oncology 2006, 1:22 http://www.ro-journal.com/content/1/1/22
Page 7 of 11
(page number not for citation purposes)
IMRT schedule for breast cancer increases the heart and
lung volumes receiving low-dose irradiation, indicating
that caution must be observed with regard to the OARs
when attempting to escalate the target dose [56]. Such an
increase in dose to the non-target breast tissue, heart and
lung would not be observed with protons. It can be
hypothesized that using a proton-SIB strategy, shorter bio-
logically equivalent schedules could be calculated and
possibly implemented in clinical use. If a planning target
volume is defined by a 1-cm margin around the surgical
cavity, the radiobiological aspects of such a strategy will
be favorable, as only a limited volume of non-involved
breast tissue (within the planning target volume) will be
treated with a high fractional dose. Parenthetically,
administering a higher fractional boost dose with protons
can be achieved with or without intensity modulation.
Using the spot scanning technology, which dynamically
position Bragg peaks, differential weights could be indi-
vidually defined within the target volume. This will allow
using these dose spots (i.e. Bragg peaks) to 'paint' the dose
as required with full flexibility. Theoretically, using inten-
sity-modulated proton therapy (IMPT), with its ability to
deliver fields of arbitrary complex fluence profiles, will
probably result in more homogeneous dose deposition
when compared to non-IMPT plans. This derives from the
fact that the highly inhomogeneous individual IMPT
fields, which when combined produces a homogeneous
dose distribution, will compensate for the dose deposi-
tion of the other field's complex 3-D dose distributions in
the optimization process. In other words, the IMPT plans
will ultimately balance more evenly the high-dose regions
around the target volume than could the non-intensity
modulated protons. No proton-SIB data for breast cancer
have been yet published. A radiobiological and treatment
planning study for breast cancer is currently being carried
out at PSI, comparing conventional schedules with IMRT-
and proton-SIB treatments. These calculations could be
useful as means of designing fractionation strategies for
use in clinical protocols with SIB with or without protons.
Finally, protons could be used for sequential boost radio-
therapy after WBI. Randomized trials have demonstrated
that local control can be significantly improved by addi-
tion of a localized tumor-bed boost delivered following
standard WBI [53,54]. In the large trial by the European
Organization for Research and Treatment of Cancer the
addition of a 16 Gy boost reduced the local failure rate by
a factor of almost 2, compared with 50 Gy WBI alone,
albeit at the cost of a greater number of fair-poor cosmetic
results [57]. Although most patients received electron-
beam boosts, results seemed similar using brachytherapy
or external photon beams. It could be argued that the lat-
eral dose fall-off may be an advantage with protons. As the
mass of protons is larger, when compared to electrons, the
angles of Coulomb interaction scattered particles are
smaller. It could be counter-argued that a larger lateral
dose fall-off could be however beneficial if the target vol-
ume is ill-defined, which is usually the case for the clinical
planning of the boost. Additionally, the logistical prob-
lems associated with a proton-boost only delivery after
breast radiotherapy with photons would be surely prohib-
itive. Protons will surely play a minor role, if any at all, in
the development of sequential boost protocols.
All forms of partial breast treatment, namely, the APBI,
sequential boost and SIB, using protons is surely a very
effective means of limiting doses to normal structures, but
this modality has a number of potential shortcomings
that must be carefully considered. First, inter- and intra-
fraction tumor motion may abrogate any ballistic advan-
tage of protons and mitigate any potential clinical benefit.
These motions during proton beam therapy can introduce
substantial unplanned heterogeneities in the dose distri-
bution throughout the target volume [58]. Specific meth-
ods of breast-dose delivery, similar to those implemented
with photon radiotherapy [59], mitigating the effects of
organ motion, should thus be actively pursued, such as
breath hold and gating methods [60]. Second, the availa-
bility of proton beam therapy for this prevalent disease is
questionable. Photons and electrons are available world-
wide and have been used in this setting for many years
unlike protons, which are restricted to a very few centers.
Third, the excellent cosmetic results achieved with mod-
ern photon therapy will not be improved with protons,
which do not deliver a lower skin dose when compared to
electrons. As mentioned earlier, the initial superficial dose
proximal to the target volume is generically 30 – 40% of
the maximum prescribed dose. More specifically, for a
superficial tumor, located 20 mm from the skin surface
and a 20 mm diameter (pT1c), the percentage of the total
dose delivered to this region would be 85 – 90%, using a
160 MeV direct proton beam. This compares identically
with the electron dose deposition, where 95% of the total
dose would be administered (applicator 10 × 10 cm) on
the skin using a 6 MeV energy electron beam. In the phase
I/II APBI clinical trial from Boston, the first 3 patients
treated with one proton field experienced acute moist
desquamation at the treatment site [52]. Subsequently, all
patients were treated with a 2 – 3 fields treatment tech-
nique. As such, sophistication of the radiation technique
using 1 proton field will not improve the cosmetic out-
come unlike photon radiotherapy for which cosmesis was
indeed favorably influenced by improved technical fac-
tors in radiation delivery in a recent series [61]. Finally,
the production of secondary neutrons produced by
nuclear interactions in the material in the beam line is a
concern with proton beam therapy. The dose produced by
these uncharged particles depends on the materials –
geometry of the beam material delivery system and the
energy of the primary proton beam [62]. Estimating theRadiation Oncology 2006, 1:22 http://www.ro-journal.com/content/1/1/22
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neutron dose by performing measurements and Monte
Carlo simulations, Schneider et al. have demonstrated
that the contribution to the integral dose from neutrons is
very low (in the order of 2 × 10-3 Sv per delivered Gy)
using the spot scanning technique [17]. This neutron-inte-
gral dose contribution, however, could be much higher
(by a factor of ten) using passive delivery systems, as a
result of the various scatterers, beam-flattening devices,
collimators and compensators that are hit by the primary
proton beam. Thus, the proton's scatterer foil technique
could substantially increase the high-LET neutron deliv-
ered integral dose, although this leakage neutron-radia-
tion could be substantially decreased with improvement
in the nozzle design. Such a nozzle-design modification
has been undertaken at the Midwest Proton Therapy
Center (Bloomington, IN, USA), with measured neutron
doses substantially lower than those from other passive
scattering delivering systems (Allan Thornton, personal
communication, 2006). This additional dose with a large
biological factor could however consequentially translate
in an increase of radiation-induced cancers.
Cost and availability of proton beam therapy
In the United States, the costs of breast conservative treat-
ment are significantly higher than those generated by
modified radical mastectomy, with or without breast
reconstruction [63]. The addition of radiation therapy
results in the higher costs of conservative surgery, repre-
senting roughly 70% of the total billing. Interestingly,
Palit et al. reported that the physician's fee for radiother-
apy were significantly higher than the surgeon's and
amounted alone to roughly one-third of the total radia-
tion therapy billing [63]. New technologies can contrib-
ute, at least theoretically, to reducing costs of breast cancer
radiotherapy; for example, multileaf collimation virtually
eliminates the need for beam blocking and reduces treat-
ment time, and particle beam delivery systems reduce the
number of treatment portals required [64]. In the majority
of cases, however, emerging technologies will ultimately
translate into increased total billing as a result of increased
time dedicated to treatment planning and the obligate
acquisition of new planning and delivery equipment,
among other factors. In general, the additional cost factor
for proton therapy over that for intensity-modulated pho-
tons is now 2.4 – 3.0 [65]. For most of the treatment plan-
ning and treatment, the costs for protons and photons are
identical. The differential costs are accounted for by the
proton accelerator and the engineering staff required for
operating the facility. It is reasonable to assume that the
expense of proton therapy per patient will decrease, as
more facilities are built and greater numbers of patients
treated. A substantial number of proton beam facilities are
currently been planned and built worldwide [66]. In the
US, these proton beam therapy facilities involve major
cancer centers such as the M.D. Anderson Cancer Center,
Houston TX, the Children's Hospital of Philadelphia,
Philadelphia PA and the University of Florida College of
Medicine, Gainesville FL, to name a few. Additionally,
accelerated proton beam therapy schedules (e.g. APBI,
SIB) may further decrease the treatment-related cost as
shown recently in a clinical trial [52]. Cost analysis of the
Boston cohort suggested that proton APBI was only mod-
estly more expensive (25%) than traditional WBI with a
sequential boost. It must be stressed that these direct costs
do not account for other aspects of treatment, such as
patient's satisfaction or quality of care. Interestingly, a
cost-effectiveness analysis of proton radiation has been
published by the Karolinska Institute group [67]. This
group used a cohort-simulation mathematical model
comparing two hypothetical cohorts of women with
breast cancer receiving either proton beam therapy or con-
ventional irradiation. The Markov-model simulated the
course of events in individual patients from diagnosis
until death or until age 100 years. Individuals were mod-
elled in differential health states, each associated with a
certain cost and utility. In this study, proton beam therapy
provided an incremental benefit for an average breast can-
cer patient. The costs and quality adjusted-life years
gained was estimated to €67,000 for proton beam ther-
apy. Base-case simulation suggested that a 2.4% and 13%
decrease of fatal cardiac disease and pneumonitis, respec-
tively, should be observed with protons when compared
to conventional irradiation. These data suggests that pro-
ton beam therapy can be cost-effective and cost saving for
specific breast cancer indications, when compared to con-
ventional radiotherapy. We now appear to be heading to
a watershed where an increased therapeutic index and
cost-effectiveness of protons come together. Although not
formally studied in a clinical setting, it is reasonable to
hypothesize that the use of proton beam therapy for high-
risk breast cancer patients could translate into less late
radiation-induced toxicity, thus improving the overall
quality of care for these patients. Likewise, decreasing the
acute side effects of radiotherapy will promote the physi-
cal well-being and early return to occupational/social
activities after treatment. Similarly, the administration of
APBI or SIB with protons could potentially decrease the
overall-treatment time and thus improve the patient's bur-
den associated with the long course of radiotherapy. The
perception that proton radiation therapy is less cost-effec-
tive than non-proton radiotherapy in specific clinical situ-
ations may be challenged by the potential for
improvements in clinical outcomes for advanced breast
cancer patients with extensive nodal involvement requir-
ing regional radiotherapy or shortened adjuvant radiation
courses (e.g. APBI or SIB) for early breast cancers.
Conclusion
Based on the analysis presented in this paper, we believe
that proton irradiation may have some potential forRadiation Oncology 2006, 1:22 http://www.ro-journal.com/content/1/1/22
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improving the outcome for patients with early and high-
risk patients alike. However, the increased cost factor and
the questionable availability of protons for such a com-
mon disease could seriously hamper their routine use for
breast cancer. Substantial additional research will be
required before a role for proton therapy in this setting
can be established. Using the methodology of dose-com-
parison analysis, the impact of protons on dose deposi-
tion for certain clinical situations should be more
thoroughly assessed, and the functional effects of dose
sparing to OAR's should be formally investigated.
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